Drug Approval | June 05, 2025
UK MHRA approves aumolertinib to treat non-small cell lung cancer
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Aumolertinib can be used in patients who have tested positive for a mutation in a gene called epidermal growth factor receptor
Regulatory filings underway for a third indication for darolutamide in prostate cancer, for finerenone in a common form of heart failure, and acoramidis in transthyretin amyloid
Enhertu now has five approved indications with the latest in HER2-expressing (IHC 3+) metastatic cancers
Over 30 years of deep life sciences industry experience with a wide range of expertise in corporate governance, capital markets, licensing and strategic collaborations
Results showed a statistically significant and clinically meaningful improvement in investigator-assessed progression-free survival
PRP is a mixture of two proenzymes, trypsinogen and chymotrypsinogen from bovine pancreas administered by intravenous injection
If approved, Tecentriq will be the first and only cancer immunotherapy available for certain people with early-stage NSCLC in Europe
Positive results reinforce the improved efficacy seen with Opdivo-based treatments in four Phase 3 clinical trials in earlier-stage cancers, including lung cancer, bladder cancer, esophageal/gastroesophageal junction cancer and melanoma
Subscribe To Our Newsletter & Stay Updated
